Sanofi announces new VP of External Affairs

pharmafile | January 30, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi 

Kathleen Tregoning has been announced as Sanofi’s vice president of External Affairs and as a new member of the Executive Committee. In the role, she will take up leadership of the firm’s External Affairs organisation which covers Market Access, Public Affairs, Government Affairs, Corporate Communications, Global Policy, and Corporate Social Responsibility.

Tregoning comes to the company from Biogen where she held the position of senior vice president of Corporate Affairs. She has held previous healthcare roles in the United States Senate and United States House of Representatives, joining Biogen in 2006 as vice president, Public Policy & Government Affairs. Throughout her career, Tregoning has amassed over 20 years of policy, advocacy, stakeholder outreach and external engagement experience.

Sanofi CEO Olivier Brandicourt said of Tregoning’s appointment: “Kathleen brings a unique set of talents and experience to Sanofi that combines a deep political and policy expertise with highly relevant corporate experience in the biopharmaceutical industry. Working closely with the entire executive leadership team, Kathleen will lead our efforts to drive a better understanding of the value of our innovations among external stakeholders and ensure appropriate market access for our various healthcare offerings.”

Tregoning will step into the role on 27 February.

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content